Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Oklahoma
M.D. Anderson Cancer Center
Mayo Clinic
Eli Lilly and Company
University Hospital, Linkoeping
University of Nebraska
Eli Lilly and Company
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Astellas Pharma Inc
M.D. Anderson Cancer Center
Guardant Health, Inc.
Nagoya University
Emory University
VA Office of Research and Development
University of Chicago